Does Farnesoid X receptor (FXR) Have a Role in NAFLD Progression ?

Background: Non-alcoholic fatty liver disease (NAFLD) is the emerging cause of chronic disease. In addition, steatosis may lead to failure obtaining sustained virological response after hepatitis C virus eradication. Therefore, there a trend identify effective strategies for managing hepatic steatosis. Farnesoid X receptor (FXR) agonists are reported play role in NAFLD treatment. Objective: This study aimed explore immunohistochemical expression FXR spectrum association with clinicopathological data. Material and method: was retrospective including 50 cases 23 normal liver. The group subdivided into 11 NAFL (simple steatosis) 39 non-alcoholic steatohepatitis (NASH). Results: Hepatocyte nuclear significantly decreased NASH (P=0.001) no significant decrease compared (P=0.149). Bile duct lower (P= 0.009) reach lowest level 0.017). group, an inverse correlation between hepatocyte ALT/AST ratio (r=-0.349 P=0.013). However, associated moderate grade severe fibrosis 0.044 P= 0.033, respectively). Conclusion: showed stepwise its from passing NAFL. has protective against progression. Elevated enzymes could be used as non-invasive method monitoring agonists' efficacy.